Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLCARDIO-ACS colchicine trial in post-acute coronary syndrome patients with persistent inflammation
ACTRN12616000400460Phase 3Recruiting
- Sponsor
- University of Sydney
- Start
- Jan 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, single-blind trial in acute coronary syndrome (ACS), coronary arteriosclerosis and atherosclerosis comparing Colchicine plus optimal medical therapy with Placebo plus optimal medical therapy (2 arms). Primary endpoints: Major adverse cardiovascular events and Processing speed. Started Jan 2022; status: recruiting.
02
Drugs
colchicine
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosisatherosclerosis
Beyond the preview
Go deeper on ACTRN12616000400460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000400460.